| VIII Conferencia Bienal Barcelona/Pittsburgh |
|
| La demencia hoy | 23-25 Mayo 2012 |
| VIII Barcelona/Pittsburgh Biennial Conference |
|
| Dementia today | 23TH-25TH May 2012 |
Agenda
Charla "La memoria y la atención. Cambios en la edad adulta" - Jornadas de Puertas Abiertas - Fundació ACE. Institut Català de Neurociències Aplicades
Fecha
22-09-2011 al 22-09-2011
Lugar
Centro Cívico Cotxeres de Sants - Barcelona - España
Organizado por
Fundació ACE. Institut Català de Neurociències Aplicades
Charla "Tipos de memoria y por qué se afectan"- "La respuesta social ante la demencia" - Jornadas de Puertas Abiertas - Fundació ACE. Institut Català de Neurociències Aplicades
Fecha
13-09-2011 al 13-09-2011
Lugar
Centro Cívico Can Deu - Barcelona - España
Organizado por
Fundació ACE. Institut Català de Neurociències Aplicades
"Ageing and Neurodegeneration"
Fecha
01-09-2011 al 04-09-2011
Lugar
Bergisch Gladbach - Alemania
Organizado por
DZNE, the German Center for Neurodegenerative Diseases and the Max Planck Institute for Biology of Ageing
Cartas
13-08-2007
The public must understand NICE balance
“Sir, You rightly point out that, in the face of finite resources, NICE (the National Institute for Health and Clinical Excellence) and the NHS have to take a rigorous approach to exploring the cost effectiveness of the treatments used (leading article, August 11). Although the Alzheimer’s drugs are cost-effective in improving cognition in people with moderate stages of the disease, your suggestion that they slow its progression is - very sadly - incorrect. There is no reliable evidence to support such a claim; and it is inherently unlikely given these drugs’ pharmacological properties. ”
Autor:
Categoría: Tratamiento
You make, though, two specific criticisms of us: that we have failed to “demand” higher total spending on drugs; and that we should “open up” our consultation processes to the public. Neither is fair.
Our advice to the NHS, on the use of new and existing medicines, has increased the drugs bill by £1.2 billion per annum. Although some consider this excessive, we remain unapologetic: by our own objective standards we consider this money to be well spent.
From the beginning, NICE has had a policy of ensuring that all our draft guidance is available for comment by anyone with an interest in the outcome, including the general public. Our independent advisory committees take all comments fully into account and often change their views. On broader social issues we also have a citizens council so as to engage with the wider public.
We have not previously, though, allowed the public to attend advisory committee meetings. We accept that opening up meetings of our advisory committees to the public would make it easier to understand how they go about reaching their conclusions. For although we publish an account of the reasoning behind their decisions, we appreciate that the underlying nuances are often impossible to capture in this way.
We are therefore actively considering putting arrangements in place for the public to have access to the meetings of all our advisory committees.
PROFESSOR SIR MICHAEL RAWLINS, Chairman, National Institute for Health and Clinical Excellence
Sir, Upholding NICE’s decision to restrict the only medication available to those in the moderate stages of this terminal disease seems short-sighted and far from cost-effective. Giving people early medication halts deterioration and keeps them functioning at a far higher level for much longer before the inevitable decline. This allows people to manage their lives without having to rely so much on other people’s care.
It is callous to force people to wait until they have lost many abilities before giving them medication that cannot retrieve so much of what has been lost. The Government relies so heavily on the thousands of carers in this country who want their loved ones to be looked after with kindness and dignity.
HAZEL LEVENTHAL, Borehamwood, Herts
Sir, My wife had Alzheimer’s diagnosed at the age of 59. It was only because we had a GP who was aware of the benefits of Aricept that my wife and I were given three and a half years together before she went into a care home.
The drugs that NICE has decided are not cost-effective have given me and my wife, and our children, time that we would not otherwise have had.
BRIAN HARRIS, Horsham, W Sussex
Fuente: Times On line








If Professor Sir Michael Rawlins' assertion that these drugs do not slow progression of the disease in its early stages is correct why is it that other countries, who presumably have also done their research, let their early-stage sufferers have access to them? Can they all be wrong and NICE be right? The cost in human misery of denying these drugs to people who would really benefit from them, despite NICE's perverse stance, is incalculable. Where would one find good residential or home care for £2.50 a day? Every member of the NICE Committee should spend at least 48 hours in the company of someone with Alzheimer's before making sweeping decisions that affect the quality of life of so many people.
Hazel Leventhal, Borehamwood, Herts
Another point is that the real figure we should be looking at is the marginal cost of manufacturing the drug. This tends to be quite low. The development cost are extremely high, but already sunk.
Malcolm McLean, Bradford, UK